T-cell receptors offer window to the cell for a new class of cancer therapeutics
Dr Daniel Kavanagh, Senior Scientific Advisor, Gene Therapies, Vaccines and Biologics at WCG, discusses how monoclonal antibodies are limited by their ability to only recognise tumour antigens expressed on the outside surface of a cell. In this article he explains how investigational genetically engineered medicinal products are leveraging T-cell receptors ...
Already a member? Sign in
